Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunotherapy

Background:

• Immune checkpoint blockade (ICB) has transformed advanced non-small cell lung carcinoma (NSCLC) treatment.
• Early ICB, particularly in the neoadjuvant setting, is hypothesized to enhance immune responses due to higher antigen load and intact lymph nodes.

Purpose of the Study:

• To review the rationale, clinical data, and future directions for neoadjuvant ICB in resectable NSCLC.
• To highlight unanswered questions critical for maximizing clinical benefits.

Main Methods:

• Review of preclinical findings and recent clinical trial data on neoadjuvant ICB in NSCLC.
• Discussion of correlative studies utilizing pre-treatment and post-resection tissue samples.

Main Results:

• Neoadjuvant ICB combined with chemotherapy improved pathological responses and event-free survival in resectable NSCLC.
• Encouraging rates of pathological downstaging were observed, supporting surgical outcomes.

Conclusions:

• Neoadjuvant ICB is a promising approach for NSCLC, enhancing treatment efficacy.
• Further investigation is required regarding optimal therapy duration, predictive clinical endpoints, and management of residual disease or recurrence.